AWS Moves Toward Selling Trainium AI Chips to Third Parties in Direct Challenge to Nvidia’s Data Center Dominance

logo

Amazon Web Services is in early talks to sell its proprietary Trainium AI chips to external companies for use in their own data centers, marking a significant potential escalation in the rivalry between AWS and Nvidia. The move was confirmed by Amazon’s AI chief Peter DeSantis, who declined to name prospective buyers, and by AWS spokesperson Doron Aronson, who acknowledged the company had historically declined such requests but was now reconsidering.

The shift stems from Amazon CEO Andy Jassy’s April shareholder letter, in which he revealed that if the company’s chip business operated as a standalone entity selling to AWS and third parties, it would generate an annual run rate of approximately $50 billion. Jassy also noted that capacity for the current Trainium chip had sold out almost immediately, as had capacity for the next generation, Trainium4, which remains more than a year from availability.

AWS has historically kept Trainium exclusive because its chips generate a compounding revenue effect on the cloud platform, with customers paying not only for AI compute but for associated storage, security, networking, and monitoring services. Selling chips externally would complicate that model and likely require manufacturing capacity that TSMC, currently dominated by Nvidia as its largest customer, may struggle to supply.

The development comes as Nvidia CEO Jensen Huang has separately identified a new $200 billion market opportunity in AI-focused CPUs, encroaching on Intel and AMD territory. Jassy’s chip ambitions represent a reciprocal pressure, with the two companies increasingly moving into each other’s core markets as AI infrastructure spending accelerates.

Need Deeper Intelligence on the AI Market?

AI Insider's Market Intelligence platform tracks funding rounds, competitive landscapes, and technology trends across the global AI ecosystem in real time. Get the data and insights your organization needs to make informed decisions.

Related Articles

gloved hands drawing vaccine from vial with syringe
Insilico Medicine Convenes an Open Consortium For Benchmark Quality in AI-Driven Drug Discovery

Insider Brief PRESS RELEASE — Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the launch of the Open

Japan’s AI Strategy: From Society 5.0 to Generative AI

A policy analysis from August 2026 Japan was arguing about the shape of its AI future before most countries had a strategy at all. In

Data Centers
Top U.S. States for AI Data Centers And Infrastructure Growth

Insider Brief The best U.S. states for AI data center growth aren’t necessarily those with the most facilities, as access to electricity, water and room

Stay Updated with AI Insider

Get the latest AI funding news, market intelligence, and industry insights delivered to your inbox weekly.

$ 0 M

Seed round tracked

Gitar — Code Validation

Get the Weekly Briefing

Funding analysis, market intelligence, and industry trends delivered to your inbox every week.

Need bespoke intelligence?

Our team combines real-time data with decades of sector experience to guide your decisions.

Subscribe today for the latest news about the AI landscape